High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Hirokazu Kobushi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Neuroblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
There is no clear consensus on the most effective treatment for relapsed/refractory high‐risk neuroblastoma (NB). We retrospectively assessed seven NB patients with relapsed/refractory disease who received high‐dose carboplatin–irinotecan–temozolomide (HD‐CIT). Five of seven patients showed favorable therapeutic response (complete remission or partial remission). Regarding toxicity, the cytopenia period tended to prolong when more than three cycles were repeated, but nonhematological toxicities were controllable with general supportive care. Due to its antitumor efficacy and well‐tolerated nonhematologic toxicity, HD‐CIT is a promising salvage chemotherapy for relapsed/refractory NB. However, it is important to pay attention to the exacerbation of hematological toxicity when repeating the regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Satoshi Saida, Katsutsugu Umeda, Hirohito Kubota, Keiji Tasaka, Itaru Kato
Zitieren
APA
Kobushi, H., Saida, S., Umeda, K., Iwai, A., Kozuki, K., Kubota, H., Tanaka, K., Obu, S., Uchihara, Y., Tasaka, K., Kato, I., Hiramatsu, H., & Takita, J. (2023). High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30331
Vancouver
Kobushi H, Saida S, Umeda K, Iwai A, Kozuki K, Kubota H, et al. High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30331
BibTeX
@article{Kobushi2023,
author = {Kobushi, Hirokazu and Saida, Satoshi and Umeda, Katsutsugu and Iwai, Atsushi and Kozuki, Kagehiro and Kubota, Hirohito and Tanaka, Kuniaki and Obu, Satoshi and Uchihara, Yoshinori and Tasaka, Keiji and Kato, Itaru and Hiramatsu, Hidefumi and Takita, Junko},
title = {High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30331}
}
EUVIMED